Feature | July 03, 2014

First Patient Enrolled in Study to Detect, Treat Vulnerable Plaques Suspected to Cause Heart Attacks

Large-scale PROSPECT II study of patients with acute coronary syndrome builds on PROSPECT study, which identified plaques at risk of causing future coronary events

Infraredx Inc. Prospect II Clinical Trial Intravascular Imaging System

July 3, 2014 — Infraredx Inc. announced the first patient enrolled in PROSPECT II, a multi-center, prospective clinical study designed to assess the ability of intravascular imaging to identify non-flow obstructing vulnerable plaques. Lipid core plaque (LCP), which is suspected to be vulnerable plaque, is a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System, a first-in-class dual modality intravascular imaging system. The study’s first patient was enrolled by David Erlinge, M.D., Ph.D., one of the study’s principal investigators, from Lund University in Sweden.

The TVC Imaging System is the only device approved by the U.D. Food and Drug Administration (FDA) to detect the presence of LCPs. The technology integrates near-infrared spectroscopy (NIRS) to detect LCPs, with enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, and is used to guide percutaneous coronary interventions (PCI).

“There is mounting clinical evidence pointing to the role of lipid-rich plaque as the main cause of heart attacks,” said Erlinge. “The PROSPECT II study will allow us to test our hypotheses that NIRS-IVUS imaging can identify the vulnerable plaques that cause heart attacks, and that preemptive treatment of the most dangerous plaques with PCI can prevent the development of further narrowing of the coronary arteries, as well as plaque erosion and rupture.”

Infraredx will provide the primary funding for the study, with additional support from The Medicines Co. and Abbott Vascular.

In 2011, the New England Journal of Medicine published results from the original PROSPECT study, which was the first to prospectively demonstrate that vulnerable plaques can be identified through imaging techniques months to years before adverse events occur. The PROSPECT II study, which will enroll 900 patients at 16 leading cardiac catherization laboratories across Scandinavia, will use the TVC Imaging System to identify vulnerable plaques in the three major coronary arteries and follow patients for at least three years to detect the occurrence of coronary events. In addition, 300 patients with “bulky” plaques (detected by intravascular ultrasound), which have been shown to be at high risk for causing future adverse events in the first PROSPECT study [1], will be randomly assigned to treatment with Abbott’s Absorb Bioresorbable Vascular Scaffold (BVS) or optimal medical therapy.

Absorb is a first-of-its-kind device which is under investigation in the United States, and received CE mark in 2011. Absorb functions similarly to a stent and is designed to open a blocked vessel and restore blood flow, but because it is made from bioresorbable materials similar to dissolving stitches, it dissolves completely over time.[1] Absorb is called a scaffold to indicate its temporary nature. In data from international studies, regression of plaque has been observed at the site where Absorb has been implanted, a unique effect not typically seen with permanent metallic stents. Data from this sub-study, termed PROSPECT-ABSORB, will be analyzed in patients with and without a cholesterol signal at the site of the large plaque, making this the first large-scale study of the identification and preventive treatment of vulnerable plaques.

The PROSPECT II study was prompted by promising new data on the ability of the TVC Imaging System to detect large vulnerable plaques precisely at the coronary artery sites at which an ST-segment elevation myocardial infarction (STEMI) occurred causing a dangerous type of heart attack.

PROSPECT II is an investigator-initiated study led by co-principal investigators Gregg W. Stone, M.D., professor of medicine, Columbia University Medical Center and co-director, Medical Research & Education Division at the Cardiovascular Research Foundation in New York; and David Erlinge, M.D., Ph.D., director of the Department of Cardiology, Lund University, Skane University Hospital in Lund, Sweden. The Cardiovascular Research Foundation (CRF) will oversee the study and provide angiographic and intravascular imaging data core lab analysis and biostatistical analysis. The Uppsala Clinical Research Center will organize and coordinate the clinical management of the trial, including patient recruitment, monitoring and data collection. Patients will be recruited through the Swedish and Norwegian Coronary Angiography and Angioplasty Register (SWEDEHEART) and the corresponding register in Denmark.

“The success of PROSPECT II would be a major step toward the goal of prospective identification and eventual treatment of the vulnerable plaques causing unanticipated coronary events,” said Stone. “Thrombosis of vulnerable plaque is the leading cause of cardiac death, myocardial infarction and heart failure, which are debilitating and costly conditions. We look forward to implementing this groundbreaking study, which has the potential to change how we approach patients with coronary artery disease.”

For more information: www.infraredx.com

References

1.Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–235

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 

News | Heart Valve Technology| December 02, 2016
December 2, 2016 — Edwards Lifesciences Corp.
Sponsored Content | Videos | Robotic Systems| November 22, 2016
Corindus Vascular Robotics received U.S.
Overlay Init